From: Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes
Characteristic | Males (n = 4) | Females (n = 17) | Total (n = 21) |
---|---|---|---|
Mean age in years (SD) | 66.25 ± 8.62 | 49.24 ± 16.68 | 52.48 ± 16.75 |
Mean age at onset in years (SD) | 66.00 ± 8.41 | 48.53 ± 15.86 | 51.86 ± 16.16 |
First symptom | |||
Ocular | 2/4 | 8/17 | 10/21 |
Bulbar | 1/4 | 7/17 | 8/21 |
Neck | 0/21 | 1/21 | 1/21 |
Limb | 1/4 | 1/17 | 2/21 |
Clinical subtypes at onset | |||
Ocular | 2/4 | 8/17 | 10/21 |
Generalized | 2/4 | 9/17 | 11/21 |
MGFA status at onset | |||
I | 2/4 | 8/17 | 10/21 |
II | 1/4 | 8/17 | 9/21 |
III | 1/4 | 1/17 | 2/21 |
IV | 0/4 | 0/17 | 0/21 |
V | 0/4 | 0/17 | 0/21 |
AChR positive | 0/4 | 1/17 | 1/21 |
RNS abnormalities | 2/4 | 14/17 | 16/21 |
Thymoma present | 0/4 | 0/17 | 0/21 |
Thymectomy | 0/4 | 0/17 | 0/21 |
Myasthenic crises | 1/4 | 5/17 | 6/21 |
Neostigmine test | 3/4 | 15/17 | 18/21 |
Medications at early follow up | |||
Pyridostigmine bromide | 1/4 | 5/17 | 6/21 |
Corticosteroids | 2/4 | 9/17 | 11/21 |
Tacrolimus | 2/4 | 0/17 | 2/21 |
Azathioprine | 0/4 | 2/17 | 2/21 |